We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
BRAF<sup>E600</sup> in benign and malignant human tumours.
- Authors
Michaloglou, C.; Vredeveld, L. C. W.; Mooi, W.J.; Peeper, D. S.
- Abstract
Of the RAF family of protein kinases, BRAF is the only member to be frequently activated by mutation in cancer. A single amino acid substitution (V600E) accounts for the vast majority and results in constitutive activation of BRAF kinase function. Its expression is required to maintain the proliferative and oncogenic characteristics of BRAFE600-expressing human tumour cells. Although BRAFE600 acts as an oncogene in the context of additional genetic lesions, in primary cells it appears to be associated rather with transient stimulation of proliferation. Eventually, BRAFE600 signalling triggers cell cycle arrest with the hallmarks of cellular senescence, as is illustrated by several recent studies in cultured cells, animal models and benign human lesions. In this review, we will discuss recent advances in our understanding of the role of BRAFE600 in benign and malignant human tumours and the implications for therapeutic intervention.Oncogene (2008) 27, 877–895; doi:10.1038/sj.onc.1210704; published online 27 August 2007
- Publication
Oncogene, 2008, Vol 27, Issue 7, p877
- ISSN
0950-9232
- Publication type
Academic Journal
- DOI
10.1038/sj.onc.1210704